You are here

Article info

Article menu
Immune cell therapies and immune cell engineering
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma

Authors

  • Lena Immisch Institute of Immunology, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Cancer Research Center, Heidelberg, GermanyGerman Cancer Consortium, partner site Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • George Papafotiou Institute of Immunology, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Cancer Research Center, Heidelberg, GermanyGerman Cancer Consortium, partner site Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Oliver Popp Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles
  • Philipp Mertins Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, GermanyBerlin Institute of Health (BIH), Berlin, Germany PubMed articlesGoogle scholar articles
  • Thomas Blankenstein Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, GermanyBerlin Institute of Health (BIH), Berlin, Germany PubMed articlesGoogle scholar articles
  • Gerald Willimsky Institute of Immunology, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Cancer Research Center, Heidelberg, GermanyGerman Cancer Consortium, partner site Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Gerald Willimsky; gerald.willimsky{at}charite.de
View Full Text

Citation

Immisch L, Papafotiou G, Popp O, et al
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma
Journal for ImmunoTherapy of Cancer 2022;10:e005535. doi: 10.1136/jitc-2022-005535

Publication history

  • Accepted October 5, 2022
  • First published October 27, 2022.
Online issue publication 
December 07, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.